Wedbush Reiterates Outperform on Dianthus Therapeutics, Maintains $46 Price Target

Benzinga · 2d ago
Wedbush analyst Laura Chico reiterates Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and maintains $46 price target.